EBOS GROUP LIMITED (EBO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

EBO

EBO - EBOS GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 2.84
Index: ASX300 | ALL-ORDS

LAST PRICE CHANGE +/- CHANGE % VOLUME

$16.71

25 Jun
2026

0.350

OPEN

$16.40

2.14%

HIGH

$16.84

89,154

LOW

$16.38

TARGET
$25.46

-0.18 change from previous day

 52.4% upside
Franking for last dividend paid out: 95%
OTHER COMPANIES IN THE SAME SECTOR
ACL . ALC . BMT . DOC . HLS . IDX . M7T . MPL . MVF . NHF . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
EBO: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx 109.8 120.5 xxx
DPS (cps) xxx 106.4 101.4 xxx
EPS Growth xxx 0.1% 9.8% xxx
DPS Growth xxx - 5.8% - 4.7% xxx
PE Ratio xxx N/A 13.8 xxx
Dividend Yield xxx N/A 6.1% xxx
Div Pay Ratio(%) xxx 96.9% 84.1% xxx

Dividend yield today if purchased 3 years ago: 3.30%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 6.40

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 27/08 - ex-div 44.81c (franking 97%)

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx109.8
DPS All xxxxxxxxxxxxxxx106.4
Sales/Revenue xxxxxxxxxxxxxxx13,486.7 M
Book Value Per Share xxxxxxxxxxxxxxx1,328.0
Net Operating Cash Flow xxxxxxxxxxxxxxx348.9 M
Net Profit Margin xxxxxxxxxxxxxxx1.67 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx8.21 %
Return on Invested Capital xxxxxxxxxxxxxxx5.13 %
Return on Assets xxxxxxxxxxxxxxx2.98 %
Return on Equity xxxxxxxxxxxxxxx8.21 %
Return on Total Capital xxxxxxxxxxxxxxx8.45 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx89.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx151 M
Long Term Debt xxxxxxxxxxxxxxx1,744 M
Total Debt xxxxxxxxxxxxxxx1,896 M
Goodwill - Gross xxxxxxxxxxxxxxx2,269 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx239 M
Price To Book Value xxxxxxxxxxxxxxx1.29

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx146.3 M
Capex % of Sales xxxxxxxxxxxxxxx1.08 %
Cost of Goods Sold xxxxxxxxxxxxxxx12,530 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx578 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx139 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

-

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

04/05/2026

1

Buy

$28.00

67.56%

Ebos Group expects $610-620m in underlying EBITDA in FY26. The company has briefed investors and set out its medium-term strategic and financial initiatives.

Ord Minnett notes operating leverage is expected to accelerate earnings growth in the medium term with further upside from bolt-on M&A.

If the company can navigate the risks around community pharmacy competition and a transition in New Zealand for Chemist Warehouse, the broker envisages a material re-rating opportunity. Buy rating. Target edges down to $28 from $29.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 91.20 cents and EPS of 120.20 cents.
Ord Minnett forecasts a full year FY27 dividend of 85.40 cents and EPS of 122.00 cents.

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Jarden

05/06/2026

2

Overweight

-

-

Jarden maintains an Overweight rating for Ebos Group with its target price reduced to NZ$30.50 from NZ$33.80 following an intermediate reset of earnings growth trajectories under new group leadership.

As the report explains, core community pharmacy segments experience distinct margin decompression from near-term supply chain fuel hikes and structural volume reallocations following the loss of the Chemist Warehouse Australia contract.

Jarden states step acquisition triggers under financial reporting frameworks alter the consolidation profile of Origin Biologics, moving the entity from an equity-accounted associate to a fully controlled subsidiary.

Operational revenues for FY26 are projected to climb to $13,657.7m, supported by resilient growth across residual medical technology lines and regional bolt-on acquisitions.

Normalised earnings per share estimates contract -8.2% in FY26 to 120.6c, capturing a deeper reset duration before core group baseline expansion is expected to resume in FY28.

FORECAST
Jarden forecasts a full year FY26 dividend of 100.00 cents and EPS of 120.60 cents.
Jarden forecasts a full year FY27 dividend of 96.00 cents and EPS of 117.00 cents.
Access Extra Coverage Research History >

EBO STOCK CHART

FNArena News on EBO

Latest Healthcare services News

1
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
2
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia
3
Ramsay Health Care: Finally A Break-Out

Nov 09 2021 - Technicals
4
Funding Overhang Weighs On Ramsay’s Rebound

Jun 10 2021 - Australia
5
Treasure Chest: More Pfizer Growth For Ebos Group

May 24 2021 - Treasure Chest
6
Treasure Chest: Demand Pumps Ramsay Health

Mar 03 2021 - Treasure Chest
7
Healius Enjoying Testing Times

Dec 11 2020 - Australia
8
The First Connection

Dec 10 2020 - Weekly Reports
9
Subdued Recovery For Ramsay Health Care

Nov 16 2020 - Australia
10
Recovery Underway For Sonic Healthcare

Jun 25 2020 - Australia